Related Experiment Videos
Persistent tardive dyskinesia associated with amoxapine therapy--two case reports
The Hillside Journal of Clinical Psychiatry
|January 1, 1986
Summary
Long-term amoxapine treatment for depression may lead to persistent tardive dyskinesia. Healthcare providers should exercise caution when prescribing amoxapine for extended periods.
Area of Science:
- Neuroscience
- Psychiatry
- Pharmacology
Background:
- Depression is a prevalent mood disorder often managed with pharmacotherapy.
- Amoxapine is a tetracyclic antidepressant used for treating major depressive disorder.
- Long-term antidepressant use necessitates ongoing evaluation for potential adverse effects.
Observation:
- Two cases are presented where patients with depression received amoxapine treatment.
- Treatment duration with amoxapine ranged from 3 to 5 years in both patients.
- Both patients subsequently developed persistent tardive dyskinesia following amoxapine therapy.
Findings:
- Prolonged administration of amoxapine (3-5 years) was associated with the onset of tardive dyskinesia.
- Tardive dyskinesia, a movement disorder, manifested persistently in the observed patients.
- This suggests a potential link between long-term amoxapine use and the development of this neurological condition.
Implications:
- The findings highlight the risk of persistent tardive dyskinesia with long-term amoxapine use.
- Clinicians should carefully consider the duration of amoxapine therapy and monitor for movement disorders.
- Further research is warranted to elucidate the mechanisms and prevalence of amoxapine-induced tardive dyskinesia.